Shares of Heron Therapeutics surged 33% to $0.39 after the company announced it will sell virtually all its commercial assets to CorMedix Therapeutics in a deal valued at roughly $223 million upfront — a figure that dwarfs Heron's pre-deal market capitalization of about $55 million. The question now: how much of that headline number actually flows to shareholders sitting on a stock that has lost more than 75% of its value in the past year?
The Deal Pays in Cash, Stock, and Promises
CorMedix will pay $145 million in cash plus 14,583,333 shares of CorMedix common stock, along with up to $55 million in contingent earn-out payments and royalties.
Based on CorMedix's November 6 closing price of $5.32, the stock component was valued at roughly $77.6 million, bringing the upfront transaction value to approximately $222.6 million. But with ~190 million Heron shares outstanding, even $222.6 million only works out to about $1.17 per share — before debt repayment and transaction costs chip away at the total.
Heron's Debt and Cash Crunch Eat Into Proceeds
Heron ended Q3 with just $23.4 million in cash.
Its working capital facility carried roughly $108 million in debt, and Rubric Capital holds about $38 million in convertible notes that will be exchanged for CorMedix shares received by Heron. After satisfying those obligations, the net proceeds shrink dramatically, explaining why the stock trades at $0.39 rather than anywhere near $1.17.
A Shell Company With a $2.3 Billion Tax Asset
After closing, Heron will exit its biotech operations but remain publicly traded, retaining approximately $2.3 billion in federal and state net operating loss carryforwards — tax credits that can offset future profits — plus CorMedix shares, royalty rights, and residual cash.
The board intends to evaluate acquiring or investing in new businesses, which may or may not be in pharmaceuticals. In essence, Heron becomes a blank-check shell whose value hinges on management's ability to redeploy a massive — but hard-to-monetize — tax asset.
The Products Were Growing; Heron Just Couldn't Afford to Wait
Heron's acute-care drugs posted 22.5% year-over-year revenue growth in Q3. Yet with revenue falling overall and cash dwindling, the company had no runway to reach profitability alone. The deal carries no financing contingency and is expected to close in Q1 2027,
with holders of roughly 22% of Heron shares already committed to vote in favor. Shareholders face a binary outcome: approve the sale and collect what's left after creditors, or reject it and ride a burning cash pile into 2027.